Clinicopathological and prognostic significance of Programmed death ligand 1 expression in Korean melanoma patients

Date 24 November 2018
Event ESMO Asia 2018 Congress
Session Poster display - Cocktail
Topics Melanoma
Personalised/Precision Medicine
Presenter Sumi Yun
Citation Annals of Oncology (2018) 29 (suppl_9): ix105-ix108. 10.1093/annonc/mdy439
Authors S. Yun1, K. Lee2, Y. Park3, S. Moon3, H.S. Lee3, G. Choe3, K.S. Lee3
  • 1Pathology, Samkwang Medical Laboratories, 06742 - Seoul/KR
  • 2Pathology, Kangwon National University Hospital, 24289 - Chuncheon-Si/KR
  • 3Pathology, Seoul National University Bundang Hospital, 13620 - Seongnam-si/KR



Programmed death ligand 1(PD-L1) expression can provide significant value to predict response following immunotherapy in several cancers. We examined the clinicopathological significance of PD-L1 expression in Korean patients with melanoma.


We investigated the expression and prognostic significance of PD-L1 and tumor infiltrating lymphocytes (TILs) in 63 patients with melanoma. We also performed a comparison of the FDA approved PD-L1 antibody (22C3 clone) and another commercially available antibody (E1L3N clone).


PD-L1 expression was found in 37 (58.7%) and closely associated with CD8+TILhigh (P < 0.001). In combined survival analysis depending on the status of PD-L1 and CD8+TILs, PD-L1-/CD8+TILhigh group showed the best outcome, and patients with PD-L1+/CD8+ TILlow showed the worst survival (P = 0.039). Furthermore, immunohistochemical results of PD-L1 expression on 22C3 and E1L3N clones showed a high concordance level (kappa value, 0.799).


Our study revealed that PD-L1 expression was closely associated with corresponding CD8+TIL status and the combined status of PD-L1 and CD8+TIL seem to be correlated with patients' survival.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Seoul National University Bundang Hospital.


02-2016-017 SNUBH Research Fund.


All authors have declared no conflicts of interest.